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Abstract— Tuberculosis (TB) is one of the deadliest diseases 
worldwide, with 1,5 million fatalities every year along with potential 
devastating effects on society, families and individuals. To address 
this alarming burden, vaccines can play a fundamental role, even 
though to date no fully effective TB vaccine really exists. Current 
treatments involve several combinations of antibiotics administered 
to TB patients for up to two years, leading often to financial issues 
and reduced therapy adherence. Along with this, the development 
and spread of drug-resistant TB strains is another big complicating 
matter. Faced with these challenges, there is an urgent need to 
explore new vaccination strategies in order to boost immunity 
against tuberculosis and shorten the duration of treatment. 
Computational modeling represents an extraordinary way to 
simulate and predict the outcome of vaccination strategies, speeding 
up the arduous process of vaccine pipeline development and relative 
time to market. Here, we present EU - funded STriTuVaD project 
computational platform able to predict the artificial immunity 
induced by RUTI and ID93/GLA-SE, two specific tuberculosis 
vaccines. Such an in silico trial will be validated through a phase 2b 
clinical trial. Moreover, STriTuVaD computational framework is 
able to inform of the reasons for failure should the vaccinations 
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strategies against M. tuberculosis under testing found not efficient, 
which will suggest possible improvements. 
Keywords—Tuberculosis, vaccine, in silico clinical trials, 
simulation  
 
I.  INTRODUCTION  
Tuberculosis (TB) is one of the top 10 causes of death around 
the globe and killed 1.7 million people in 2016, according to the 
World Health Organization [1]. Spread through the air, it takes 
just a sneeze or cough to diffuse from one person to another one 
[2]. Most fatalities occur in poorer countries even though no 
population today is immune or isolated from the risk to be 
affected by TB [3]. To date non fully effective TB vaccines 
exists and, despite being both preventable and curable, it can be 
difficult for TB infected patients to get live-saving care [4]. 
Current treatment can involve antibiotics administration for up 
to two years, potentially becoming a financial and social burden 
and resulting in patients stopping their medication [5]. At times, 
TB is not diagnosed and dealt with the development and spread 
of drug-resistant strains [6], [7].  
Faced with these challenges, several EU-funded projects are 
working to identify and maximize the potentiality of novel 
vaccines in order to save lives, stem the spread of infection and 
shorten treatment. In this context, the HORIZON 2020- 
STriTuVaD project is leading the way to fight against TB 
through the development of an innovative technology named 
Universal Immune System Simulator (UISS), based on a 
computational modeling infrastructure able to simulate and 
predict the outcome of two specific vaccination strategies, i.e., 
RUTI vaccine and ID93+GLA-SE vaccine [8], [9] along with 
the relevant individual human physiology and physiopathology 
of patients affected by Mycobacterium tuberculosis (MTB).  
To this aim we generated a set of digital populations of 
individuals providing a reliable prediction of phase III outcomes 
on the basis of the data collected during the phase II clinical trial, 
as agreed in the project. 
To analyze the behavior of possible therapeutic 
interventions, we implemented mechanisms of action (MoA) of 
ID93+GLA-SE vaccine in our pre-existing version of UISS-TB 
computational platform, in which RUTI vaccine was previously 
implemented [10], along with the entire dynamics of MTB and 
interactions with the immune system machinery. We analysed 
the associated immune response induced by both vaccines and 
we applied UISS-TB computational model to set up a library of 
digital TB patients, through the identification of a “vector of 
features” that combines biological and pathophysiological 
parameters of tuberculosis patients. 
In this scenario, our simulation infrastructure was also able 
to reveal few not-responders patients after TB vaccines 
administration. 
 
 
II. MATERIALS AND METHODS 
 
A. Universal Immune System Simulator (UISS) 
The computational platform is represented by the Universal 
Immune System Simulator (UISS), a multi-scale (cellular and 
molecular level), multi-compartment, polyclonal agent based 
simulator of the immune system dynamics [11]. Cellular entities 
can take up a state from a certain set of suitable states and their 
dynamics is realized by means of state changes. They include 
lymphocytes (i.e. B lymphocytes, helper, cytotoxic and 
regulatory T lymphocytes and natural killer cells) and 
monocytes (i.e. macrophages (M) and dendritic cells). For what 
concerns molecules, the model distinguishes between simple 
small molecules like interleukins or signaling molecules in 
general and more complex molecules like immunoglobulins and 
antigens. At the same level of entities, UISS implements 
immune system activities. They include both interactions and 
functions, referring respectively to the main immune system 
tasks. Moreover, UISS represents receptors and ligands as bit 
strings and use a string matching rule to model affinity. In 
particular, specificity is implemented in UISS by a bit-string 
polyclonal lattice method [12].  
In this context, UISS was extended to consider immune 
system dynamics at a large scale. This was achieved extending 
UISS platform in three critical points: i) the peripheral blood 
compartment increased in size in order to deal with a 
representative portion of peripheral blood and included immune 
system entities circulating through it; ii) immune system 
repertoire implementation in order to take into account an 
immune system potential diversity at human natural scale i.e. 
about 1020 order magnitude of T and B cells clonotypes; iii) 
compartments addition to simulate critical organs targeted by 
tuberculosis i.e., lungs and near lymph nodes.  
UISS web-interface is developed using the Flask micro-
server environment and Python programming language. Figure 
1 shows a screenshot of the web Graphic User Interface (GUI) 
in which it is possible to set different combinations of cellular 
and non-cellular parameters. The simulation will be performed 
asynchronously. This allows to launch the process separately 
from the main thread, notifying the user when the simulation is 
finished and performing multiple simulations simultaneously.  
 
Figure 1. UISS web-GUI. On the left, one can see a set of biological and 
physiopathological parameters, referring to the vector of features created for the 
personalization of TB digital patients. On the right, one can see a box called 
"your simulations", containing the list of all the simulations, sorted by their 
creation date and classified in “in execution” or in “completed” status. 
 
B. TB vaccines  
To analyze the behavior of a possible therapeutic 
intervention, we simulated through our modeling infrastructure 
the two vaccines we are going to test inside the STriTuVaD 
project i.e., RUTI (developed by Archivel Farma S.L.) and 
ID93/GLA-SE (developed by Infectious Disease Research 
Institute (IDRI)) vaccines. To this end, we implemented inside 
UISS ID93/GLA-SE mechanism of action (MoA). 
For the sake of completeness, RUTI is a polyantigenic 
liposomal vaccine made of detoxified, fragmented M. 
tuberculosis cells (FCMtb), while ID93/GLA-SE consists of a 
fusion of four M. tuberculosis proteins: Rv1813, Rv2608, 
Rv3619, and Rv3620. The vaccination strategy includes also the 
GLA-SE adjuvant. 
We modeled the immune response induced by one boost of 
25ug dosage of RUTI and two boosts of 100ng, with the second 
dosage two months later after the first one for ID93/GLA-SE, 
accordingly to the clinical trial protocol as agreed in the 
STriTuVaD project. 
 
C. Generation of libraries of digital patients  
To reproduce biological diversity of TB patients, an 
appropriate procedure for the generation of libraries of digital 
patients has been developed. This has been achieved through the 
implementation of three specific strategies: i) the creation of the 
initial immune system repertoire in a stochastic way taking also 
into account the DNA fragments assembly and Class I or Class 
II HLA patterns; ii) the simulation of immune system 
interactions; iii) the identification of a “vector of features” that 
associates both biological and pathophysiological parameters 
that personalize the digital patient and reproduce the physiology 
and the pathophysiology of TB patients.  
The first is the creation of the initial immune system 
repertoire, generated in a way that simulates the DNA fragments 
assembly accounting for the inherent stochasticity of the 
process, but also on the presence of the Class I or Class II HLA 
patterns. The second is related to the simulation of immune 
system interactions. These take place in a different order, 
according to a sequence that depends on a series of events whose 
generated from a selection of a random seed. This imitates, to 
some extent, the randomness of the immune response in the 
initial phases, where innate immunity takes place (consider, for 
example, the case that a fully matching CD4 T cell is present at 
the specific lymph node where a DC is presenting the processed 
antigen). The last approach is represented by the identification 
of a “vector of features” that defines a specific patient through a 
vector of 26 features as follows: 1) drug Sensitive (DS)/multi-
drug resistant (MDR); 2) bacteria Load (BL) in sputum; 3) MTB 
strain; 4) CD4-Th1; 5) CD4-Th2; 6) IgG titers; 7) CD8 T cells; 
8) IL-1; 9) IL-2; 10) IL-10; 11) IL-12; 12) IL-17; 13) IL-23; 14) 
IFN Type I: 15) IFN-γ; 16) TNF-α; 17) TGF-β; 18) LXA4; 19) 
PGE2; 20) Chemokines; 21) Vitamin D; 22) HLA-1; 23) HLA-
2; 24) FoxP3; 25) Age; 26) BMI.  
 
III. RESULTS 
 
We run a total of 60 simulations i.e., 30 for digital in silico 
patients treated with RUTI vaccine and 30 for digital in silico 
patients treated with ID93/GLA-SE. Simulation results of UISS-
TB applied to the sample set of digital in silico patients are 
shown in the following figures. We present, for each biological 
entity, both the mean behavior and the +/- SD (blue lines). 
The average effects of the vaccination based on RUTI 
vaccine and the ones based on ID93/GLA-SE vaccine are 
shown, taking into account the alveolar macrophages (AM) 
dynamics, CD4 Th1, IFN-γ and immunoglobulins levels. Figure 
2 shows the alveolar macrophage dynamics after RUTI 
administration accordingly to one of the approved protocol. We 
can observe that the average necrotic AM population is 
considerably reduced indicating an effective immune response 
elicited by RUTI vaccine, decreasing the probability of disease 
reactivation.  
 
 
 
Figure 2. AM population detailed dynamics with RUTI vaccine administration. 
 
 
Figure 3 shows the alveolar macrophage dynamics after 
ID93/GLA-SE administration. We can observe that the average 
necrotic AM population is considerably reduced indicating an 
effective immune response elicited by this vaccination strategy, 
decreasing the probability of disease reactivation. 
Then, in figure 4, a strong Th1 response is induced with a 
down-regulation of Th2 response, with the induction of 
immunological memory, after RUTI administration, while in 
figure 5 high levels of IFN-γ are present, in good agreement with 
the results presented in specific literature.  
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Figure 3. AM population detailed dynamics with ID93/GLA-SE vaccine 
administration. 
 
 
Figure 4. CD4 T cell population detailed dynamics after RUTI vaccine 
administration. 
 
 
Figure 5. IFN-γ levels after RUTI administration. 
 
Then, after ID93/GLA-SE administration, a strong Th1 
response is induced with a down-regulation of Th2 response, 
along with the induction of immunological memory as depicted 
in figure 6, while in figure 7 high levels of IFN-γ are present, in 
good agreement with the results presented in specific literature. 
 
 
Figure 6. CD4 T cell population detailed dynamics after ID93/GLA-SE vaccine 
administration. 
 
 
Figure 7. IFN-γ levels after ID93/GLA-SE administration. 
 
It is worth to mention that, looking at the +/- SD data, UISS-
TB is able to identify few digital in silico patients that are 
actually not responding to vaccines stimuli. As an example, we 
reported in figures 8 and 9 the AM population dynamics, CD4 T 
cell population dynamics and IFN-γ levels of a specific case of 
not responder, respectively for RUTI and ID93/GLA-SE 
vaccine.  
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Summarizing, UISS-TB reveals that not-responders patients 
are identified by insufficient CD4 T cell Type 1 response along 
with the correspondent low levels of IFN-γ. This could depend 
on specific patient immune system repertoire that do not allow 
an efficient antigen presentation process followed by an 
impaired CD4 T cell response.  
 
 
 
 
Figure 8. AM population dynamics, CD4 T cell population dynamics and IFN-
gamma levels in a not responder case after RUTI administration. 
 
 
 
Figure 9. AM population dynamics, CD4 T cell population dynamics and IFN-
gamma levels in a not responder case after ID93/GLA-SE administration. 
 
 
IV. CONCLUSIONS 
UISS-TB, the simulation platform employed in STriTuVaD 
project, has revealed a very good ability to capture the essential 
immune system responsiveness elicited by two specific 
vaccination strategies against tuberculosis disease. Moreover, 
UISS was able to identify few cases of bad responders 
accordingly to the specificity of CD4 T cell dynamics. This 
could represent a strong evidence for a successful clinical trial.  
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